TY - JOUR
T1 - "I do feel like a scientist at times"
T2 - A qualitative study of the acceptability of molecular point-of-care testing for chlamydia and gonorrhoea to primary care professionals in a remote high STI burden setting
AU - Natoli, Lisa
AU - Guy, Rebecca J.
AU - Shephard, Mark
AU - Causer, Louise
AU - Badman, Steven G.
AU - Hengel, Belinda
AU - Tangey, Annie
AU - Ward, James
AU - Coburn, Tony
AU - Anderson, David
AU - Kaldor, John
AU - Maher, Lisa
AU - Donovan, Basil
AU - Wilson, David
AU - Regan, David
AU - Wand, Handan
AU - Whiley, David
AU - Tabrizi, Sepehr N.
AU - Fairley, Christopher
AU - TTANGO Investigators
N1 - Funding Information:
TTANGO is funded by a National Health and Medical Research Council (NHMRC) Project Grant #109902. The Kirby Institute receives funding from the Australian Government Department of Health and Ageing.We gratefully acknowledge the contribution to this work of the Victorian Operational Infrastructure Support Program received by the Burnet Institute. TTANGO is a collaboration between researchers named in the authorship list, additional TTANGO investigators not named as authors (Basil Donovan, David Wilson, David Regan, Handan Wand from the Kirby Institute; David Whiley, The Queensland Paediatric Infectious Diseases Laboratory; Sepehr N. Tabrizi, The Royal Women?s Hospital; Christopher Fairley, Monash University) and the Queensland Aboriginal and Islander Health Council; Queensland Health; Aboriginal Health Council ofWestern Australia; West Australia Department of Health; West Australian Country Health Service; Aboriginal Health Council of South Australia; South Australia Health; National Reference Laboratory; and Medical Communication Associates. We are grateful to Cepheid for their generous in-kind support.
PY - 2015/12/1
Y1 - 2015/12/1
N2 - Background Point-of-care tests for chlamydia (CT) and gonorrhoea (NG) could increase the uptake and timeliness of testing and treatment, contribute to improved disease control and reduce reproductive morbidity. The GeneXpert (Xpert CT/NG assay), suited to use at the pointof- care, is being used in the TTANGO randomised controlled trial (RCT) in 12 remote Australian health services with a high burden of sexually transmissible infections (STIs). This represents the first ever routine use of a molecular point-of-care diagnostic for STIs in primary care. The purpose of this study was to explore the acceptability of the GeneXpert to primary care staff in remote Australia. Methods In-depth qualitative interviews were conducted with 16 staff (registered or enrolled nurses and Aboriginal Health Workers/Practitioners) trained and experienced with GeneXpert testing. Interviews were digitally-recorded and transcribed verbatim prior to content analysis. Results Most participants displayed positive attitudes, indicating the test was both easy to use and useful in their clinical context. Participants indicated that point-of-care testing had improved management of STIs, resulting in more timely and targeted treatment, earlier commencement of partner notification, and reduced follow up efforts associated with client recall. Staff expressed confidence in point-of-care test results and treating patients on this basis, and reported greater job satisfaction. While point-of-care testing did not negatively impact on client flow, several found the manual documentation processes time consuming, suggesting that improved electronic connectivity and test result transfer between the GeneXpert and patient management systems could overcome this. Managing positive test results in a shorter time frame was challenging for some but most found it satisfying to complete episodes of care more quickly. Conclusions In the context of a RCT, health professionals working in remote primary care in Australia found the GeneXpert highly acceptable. These findings have implications for use in other primary care settings around the world.
AB - Background Point-of-care tests for chlamydia (CT) and gonorrhoea (NG) could increase the uptake and timeliness of testing and treatment, contribute to improved disease control and reduce reproductive morbidity. The GeneXpert (Xpert CT/NG assay), suited to use at the pointof- care, is being used in the TTANGO randomised controlled trial (RCT) in 12 remote Australian health services with a high burden of sexually transmissible infections (STIs). This represents the first ever routine use of a molecular point-of-care diagnostic for STIs in primary care. The purpose of this study was to explore the acceptability of the GeneXpert to primary care staff in remote Australia. Methods In-depth qualitative interviews were conducted with 16 staff (registered or enrolled nurses and Aboriginal Health Workers/Practitioners) trained and experienced with GeneXpert testing. Interviews were digitally-recorded and transcribed verbatim prior to content analysis. Results Most participants displayed positive attitudes, indicating the test was both easy to use and useful in their clinical context. Participants indicated that point-of-care testing had improved management of STIs, resulting in more timely and targeted treatment, earlier commencement of partner notification, and reduced follow up efforts associated with client recall. Staff expressed confidence in point-of-care test results and treating patients on this basis, and reported greater job satisfaction. While point-of-care testing did not negatively impact on client flow, several found the manual documentation processes time consuming, suggesting that improved electronic connectivity and test result transfer between the GeneXpert and patient management systems could overcome this. Managing positive test results in a shorter time frame was challenging for some but most found it satisfying to complete episodes of care more quickly. Conclusions In the context of a RCT, health professionals working in remote primary care in Australia found the GeneXpert highly acceptable. These findings have implications for use in other primary care settings around the world.
UR - http://www.scopus.com/inward/record.url?scp=84957563251&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0145993
DO - 10.1371/journal.pone.0145993
M3 - Article
C2 - 26713441
AN - SCOPUS:84957563251
VL - 10
JO - PLoS ONE
JF - PLoS ONE
SN - 1932-6203
IS - 12
M1 - e0145993
ER -